Paper1320366
In vitro activities of five quinolones against Chlamydia pneumoniae.
Hammerschlag MR and 2 others. Antimicrob Agents Chemother, 1992. Cited by 54 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. In vitro activities of five quinolones against Chlamydia pneumoniae. Papers, record 1320366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1320366
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Infective Agents | Major topic |
| Chlamydophila pneumoniae | Major topic |
| Ciprofloxacin | Major topic |
| Fleroxacin | Major topic |
| Fluoroquinolones | Major topic |
| Ofloxacin | Major topic |
| Quinolones | Major topic |
| Microbial Sensitivity Tests |
Source PubMed
References8
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1,571,425 | Persistent infection with Chlamydia pneumoniae following acute respiratory illness. | Clin Infect Dis | 1992 | https://conductscience.org/library/papers/1571425 | PubMed |
| 2 | 2,010,629 | Infection with Chlamydia pneumoniae in Brooklyn. | J Infect Dis | 1991 | https://conductscience.org/library/papers/2010629 | PubMed |
| 3 | 2,118,330 | In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens. | Antimicrob Agents Chemother | 1990 | https://conductscience.org/library/papers/2118330 | PubMed |
| 4 | 3,058,015 | Susceptibility testing of Chlamydia trachomatis: from eggs to monoclonal antibodies. | Antimicrob Agents Chemother | 1988 | https://conductscience.org/library/papers/3058015 | PubMed |
| 5 | 2,252,040 | Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. | Am J Med | 1990 | https://conductscience.org/library/papers/2252040 | PubMed |
| 6 | 2,672,243 | Tissue penetration of the new quinolones in humans. | Rev Infect Dis | 1989 | https://conductscience.org/library/papers/2672243 | PubMed |
| 7 | 2,817,862 | In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2817862 | PubMed |
| 8 | 2,181,028 | A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. | J Infect Dis | 1990 | https://conductscience.org/library/papers/2181028 | PubMed |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 19,332,673 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. | Antimicrob Agents Chemother | 2009 | https://conductscience.org/library/papers/19332673 | PubMed |
| 17,122,017 | Isolation and antimicrobial susceptibilities of Chlamydial isolates from Western barred bandicoots. | J Clin Microbiol | 2007 | https://conductscience.org/library/papers/17122017 | PubMed |
| 11,796,366 | In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/11796366 | PubMed |
| 11,600,398 | In vitro and in vivo activities of sitafloxacin against Chlamydia spp. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11600398 | PubMed |
| 10,553,711 | Activity of quinolones against Chlamydia pneumoniae. | Drugs | 1999 | https://conductscience.org/library/papers/10553711 | PubMed |
| 10,471,577 | In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. | Antimicrob Agents Chemother | 1999 | https://conductscience.org/library/papers/10471577 | PubMed |
| 9,559,818 | In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9559818 | PubMed |
| 9,303,410 | In vitro activity of trovafloxacin against Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9303410 | PubMed |
| 9,174,194 | In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9174194 | PubMed |
| 9,087,506 | In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9087506 | PubMed |
| 8,913,488 | In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1996 | https://conductscience.org/library/papers/8913488 | PubMed |
| 8,851,610 | Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. | Antimicrob Agents Chemother | 1996 | https://conductscience.org/library/papers/8851610 | PubMed |
| 8,665,464 | Chlamydia pneumoniae (TWAR). | Clin Microbiol Rev | 1995 | https://conductscience.org/library/papers/8665464 | PubMed |
| 8,540,698 | Relevance of Chlamydia pneumoniae murine pneumonitis model to evaluation of antimicrobial agents. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/8540698 | PubMed |
| 8,494,377 | In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8494377 | PubMed |
| 8,092,845 | In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/8092845 | PubMed |
| 7,986,006 | Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/7986006 | PubMed |
| 7,810,992 | Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/7810992 | PubMed |
| 7,689,439 | The future of the quinolones. | Drugs | 1993 | https://conductscience.org/library/papers/7689439 | PubMed |
| 7,601,015 | Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections. | Drugs | 1995 | https://conductscience.org/library/papers/7601015 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1320366
GET https://conductscience.org/api/papers/v1/1320366/cited_by?page=2